Select Page


Lung Cancer Summit

Virtual Live Conference

October 13

Live from University Hospital Geneva






Register HereView Agenda Here

Alfredo Addeo, MD
Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Solange Peters, MD-PhD
Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 3rd edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Italy, South Africa, India and Switzerland.

This meeting is accredited and CME-certified by the Swiss Society of Medical Oncology with 5 credit points. Join us and get your certificate of attendance during the meeting.

5 SGMO CME Credits


Wednesday, 13 October 2021

Indicated Time Zone: Central European Time (CET)


Welcome by Chairs

Solange Peters & Alfredo Addeo (Switzerland)


Latest treatment updates for frontline non-oncogene addicted NSCLC

Hossein Borghaei (USA)


How do we tailor treatments for later lines of therapy in the IO era

Giuseppe Banna (United Kingdom)


Integrating immunotherapy into localized NSCLC

Antonio Calles (Spain)


Open discussion & coffee break


Current standard of care and challenges in Small Cell Lung Cancer

Alessandra Curioni (Switzerland)


The art of balance: approaching immune-related adverse events in thoracic oncology

Jarushka Naidoo (Ireland)


Lunch / Industry Symposium Eli Lilly


State of the art in biopsy testing: the paths we set for lung cancer treatment

Stephen Finn (Ireland)


The latest on targeting EGFR+ Non-Small Cell Lung Cancer

Vanita Noronha (India)


ALK+ and ROS1: what TKI is suitable for what patient?

Alex Friedlaender (Switzerland)


Open discussion & coffee break


KRAS and HER2: Expanding the horizons for the treatment of lung cancer

Christine Lovly (USA)


RET, MET, NTRK… a new era for targeted therapies in all mutations?

Ronwyn van Eeden (South Africa)


Wrap up & Final Questions

Solange Peters & Alfredo Addeo (Switzerland)

The International Lung Cancer Summit 2021 is made possible with the kind support by our partners with no influence on the content:

MSD Logo
Eli Lilly Logo
AstraZeneca Logo
Amgen Logo
Novartis Logo
Bayer Logo
Janssen Logo
Pfizer Logo
Roche Logo
Takeda Logo
BMS Logo
Frontiers Logo
Sanofi Genzyme Logo
Merck Logo








Save The Date And Follow Us For The Latest News

We'll be joined by @DralexGva at our next #LungSummit this October 13th!

Be sure to catch the live discussion on #TKIs - which one is suitable for what patient?

Register for free ➡️

Image for the Tweet beginning: We'll be joined by @DralexGva at

Immunotherapy for #NSCLC is continually evolving.

Be sure to catch @Tony_Calles this October 13th and discuss the latest behind integrating #immunotherapy into localized #NSCLC at our next #LungSummit. 

Register for free ➡️

Image for the Tweet beginning: Immunotherapy for #NSCLC is continually

We're delighted to partner with @FrontOncology this year at our annual #LungSummit to bring #openaccess research and medical education to health care professionals!

Check out the journal ➡️

Register for the #LungSummit ➡️

Image for the Tweet beginning: We're delighted to partner with

Another #TBT to last year's #LungSummit!

Check out @Alfdoc2 and @JackWestMD on how co-mutations should be factored into treatment decision making.

We look forward to discussing new advances in #lungcancer treatment at our next #LungSummit!

Register ➡️

Image for the Tweet beginning: Another #TBT to last year's

#ThrowbackThursday to last year's #LungSummit w/ @Jbauml on targeted therapies for #NSCLC.

A lot happened this past year, w/ newer approaches introduced for the treatment of #lungcancer. We look forward to discussing these more on Oct. 13th!

Join us ➡️

Image for the Tweet beginning: #ThrowbackThursday to last year's #LungSummit

Immune-related adverse events (#irAEs) are diverse, and for patients with #lungcancer, immune-mediated lung injury may occur in those receiving #immunotherapy. 

Discuss more irAEs with @DrJNaidoo this October 13th at our annual #LungSummit!

Register ➡️

Image for the Tweet beginning: Immune-related adverse events (#irAEs) are

How do we tailor treatments for later lines of therapy in the immuno-oncology era?

Connect and discuss the latest developments of targeted drugs and #tumor resistance mechanisms with @gbanna74 at our annual #LungSummit, this October 13th!

Register now ➡️

Image for the Tweet beginning: How do we tailor treatments
Load More...